Abstract
Purpose :
There are few reports regarding outcomes in sequential and simultaneous bilateral rhegmatogenous retinal detachment (BRRD) repair. We performed this retrospective cohort study to assess the anatomical and functional outcomes in BRRD repair.
Methods :
Patients diagnosed with BRRD between 2014 and 2020 at the CHU de Québec – Université Laval were reviewed. We excluded patients with other etiologies (e.g., diabetic retinopathy, tractional retinal detachment (RD), exudative RD) and patients with previous vitreoretinal surgeries. There were 218 eyes of 109 patients. Of these, 86 (79%) were male and median [Q1, Q3] age at presentation for the first eye was 60 [54, 66] years. Data include patient demographics, preoperative characteristics, intraoperative management, single surgery anatomic success (SSAS), complications, and final pinhole visual acuity (PHVA) in logarithm of the minimal angle of resolution (logMAR).
Results :
Of the 109 patients included, 92% (n=100) had sequential BRRD and 8% (n=9) simultaneous BRRD. Simultaneous BRRD patients were more likely to have high myopia (simultaneous: 78% vs. sequential: 23%; p<0.001) and half of them (n=5, 56%) had unilateral symptoms only. Between first and second eye RD, median [Q1, Q3] duration of symptoms was shorter for the second eye compared to the first (first: 7 [3, 15] days vs. second: 4 [2, 10] days; p=0.028). Second eyes also had less retinal tears (first: 2.94 ± 2.76 tears vs. second: 2.38 ± 1.79 tears; p=0.031) and better median [Q1, Q3] PHVA at presentation (first: 0.46 [0.14, 2.30] vs. second: 0.24 [0.06, 0.95]; p=0.012). SSAS was 92% (n=100) and 93% (n=101) for the first and second eye, respectively (p=1.00). Both eyes improved visual acuity with comparable PHVA at 3 months (first: 0.30 [0.14, 0.48] vs. second: 0.34 [0.13, 0.70]; p=0.36). Final PHVA was however better for the first eye (first: 0.14 [0.04, 0.30] vs. second: 0.20 [0.04, 0.43]; p=0.010). Complication rates were similar between both eyes (first: n=1, 1% vs. second: n=2, 1.8%).
Conclusions :
In this BRRD cohort, SSAS was similar for both eyes. The subsequent eye was more likely to be treated earlier with less advanced presentations, but at 3 months, PHVA was not significantly different between eyes. Difference in final PHVA may be attributable to longer follow-up in first eyes.
This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.